Open access

2 The multi-physics automated reconfigurable separation (MARS®) system provides high purity, high recovery and high throughput enrichment of immune cells for immunotherapy
Liping Yu, Gregory Schneider, Alice Wang

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A1-A2; DOI: 10.1136/jitc-2020-SITC2020.0002
19 Whole-exome sequencing based immunogenomic profiling with potential clinical applicability in circulating cell-free DNA and tissue from advanced stage colorectal cancer patients
Zheng Feng, Juergen Scheuenpflug, Mengyao Tan, Danyi Wang

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A10-A11; DOI: 10.1136/jitc-2020-SITC2020.0019
18 New method of assessing tumor heterogeneity utilizing both circulating tumor DNA and tissue DNA to predict the response to immunotherapy
Jaeyoun Choi, Myungwoo Nam, Stanislav Fridland, Jinyoung Hwang, Chan Mi Jung, Christmann Low, Young Kwang Chae

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A10; DOI: 10.1136/jitc-2020-SITC2020.0018
182 Highly potent fully human anti-VISTA antibodies – a new target checkpoint inhibitor against immunosuppressive myeloid cells
Thierry Guillaudeux, Eric Tarcha, Robert Bader, Benjamin Dutzar, Nathan Eyde, Emily Frazier, David Jurchen, Remington Lance, Cristina Loomis, Kurt Lustig, Yulia Ovechkina, David Peckham, Shaarwari Sridhar, Mei Xu, Shawn Iadonato, Thierry Guillaudeux, Jeff Posakony

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A108; DOI: 10.1136/jitc-2020-SITC2020.0182
184 Two types of anti-TIGIT antibodies with distinct binding epitope and functional activities
Tingting Zhong, Xinghua Pang, Zhaoliang Huang, Na Chen, Xiaoping Jin, Yu Xia, Maxwell Zhongmin Wang, Baiyong Li

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A109; DOI: 10.1136/jitc-2020-SITC2020.0184
185 Camrelizumab monotherapy or combination therapy in patients with recurrent or metastatic cervical and endometrial carcinoma:a retrospective study
Hong Liu, Shuhuai Niu, Zhaohui Fang, Xi Chen, Qianying Zhang

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A109-A110; DOI: 10.1136/jitc-2020-SITC2020.0185
186 Distinct immune signatures predicting clinical response to PD-1 blockade therapy in gynecological cancers revealed by high-dimensional immune profiling
Yuki Muroyama, Yuki Muroyama, Sasikanth Manne, Alexandar Huang, Divij Mathew, Lakshmi Chilukuri, Allison Greenplate, Takuya Ohtani, Dmitriy Zamarin, Claire Friedman, John Wherry

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A110; DOI: 10.1136/jitc-2020-SITC2020.0186
187 Real-world treatment patterns and clinical predictors of overall survival among anti-PD-1 exposed advanced melanoma patients with documented evidence of disease progression
Cathy Anne Pinto, Xinyue Liu, Xiaoyun Li, Emilie Scherrer, Mizuho Kalabis

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A110-A111; DOI: 10.1136/jitc-2020-SITC2020.0187
188 Novel Anti-SIRpalpha antibodies with differentiated characteristics as promising cancer therapeutics
Minu K Srivastava, Ryan Alvarado, Sushma Krishnan, Christine Tan, Swati Jalgaonkar, George Huang, Erin L Filbert, Frances R Bahjat, Xiaodong Yang

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A111; DOI: 10.1136/jitc-2020-SITC2020.0188
190 Timing of steroid doses and response rates to immune-checkpoint inhibitors in metastatic cancer
Karine Tawagi, Diana Maslov, Victoria Simenson, Helen Yuan, Cameron Parent, Adi Bamnolker, Richa Goel, Zoe Blake, KC Madhav, Marc Matrana, Karine Tawagi, Daniel Johnson, Karine Tawagi

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A112; DOI: 10.1136/jitc-2020-SITC2020.0190

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages